Nov 29 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Valeant announces the initiation of a primary care sales force for Xifaxan and Relistor
* Says costs of program were considered in previously announced guidance for full year 2016 Source text for Eikon: ID:nCNWXG1Gpa Further company coverage: VRX.TO